ObesityWeek 2026 Preview: CagriSema, Childhood Semaglutide and “Food Noise” Data to Watch

Clinical Trial Tracker · Reviewed by Thomas Okafor, PhD · Published November 4, 2026

Lower-dose CagriSema, semaglutide in children as young as six, and the first real-world numbers for the Wegovy pill are all on the program at ObesityWeek 2026, which opens in ten days. The meeting, hosted by The Obesity Society, lists more than 175 scientific sessions and 700 posters [1]. Most of what’s announced so far comes from Novo Nordisk, which says it will bring 26 abstracts [2].

The schedule at a glance

Times are from Novo Nordisk’s October 29 announcement [2].

REDEFINE 9: CagriSema at lower doses

CagriSema pairs semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting version of amylin, a hormone released alongside insulin that signals fullness. All of the main phase 3 trials used the full 2.4 mg/2.4 mg dose. REDEFINE 9 tests two lower doses, 1.7/1.7 mg and 1.0/1.0 mg, and Novo describes this as the trial’s primary results [2]. Lower doses are relevant for people who can’t tolerate the full dose; in REDEFINE 1, gastrointestinal side effects affected 79.6% of people on CagriSema against 39.9% on placebo [3].

STEP Young: semaglutide in younger children

Semaglutide injection is approved for adolescents in the US, but not for children under 12. STEP Young tested it in children aged 6 to under 12, and Novo says full results will be published at the same time as the oral presentation on November 16 [2]. Expect attention on growth, nutrition and side effects as well as weight, since data in this age group are thin.

Real-world data on the Wegovy pill

Several posters look at oral semaglutide outside trials, including a digital support cohort (SWEEP), three-month outcomes through telehealth, and preferences of adults over and under 65 [2]. Real-world data show who starts a drug and how they fare without trial-level support, though these analyses are observational and sponsored by the manufacturer.

Measuring “food noise”

Two posters measure “food noise,” the term patients use for intrusive, persistent thoughts about food. One reports three-month scores on oral semaglutide; another tracks food noise and weight with the injection through telehealth [2]. It’s a patient-reported measure that researchers are still standardizing, which makes these early numbers interesting but hard to compare across studies.

Reading conference data

Conference abstracts are short, often not peer reviewed in full, and usually sponsored. Novo’s own release notes that CagriSema “is not approved in the United States or anywhere else” [2]. We’ll report the presented numbers after November 17, alongside any peer-reviewed papers. For how the competing drugs compare so far, see our coverage of retatrutide vs semaglutide and our tirzepatide guide.

This preview reports on upcoming conference data for readers’ information and doesn’t replace a clinician’s advice.